U.S. Markets open in 8 hrs 57 mins
  • S&P Futures

    3,408.00
    -24.50 (-0.71%)
     
  • Dow Futures

    27,941.00
    -193.00 (-0.69%)
     
  • Nasdaq Futures

    11,615.00
    -76.25 (-0.65%)
     
  • Russell 2000 Futures

    1,591.60
    -11.50 (-0.72%)
     
  • Crude Oil

    39.81
    -0.22 (-0.55%)
     
  • Gold

    1,916.10
    -13.40 (-0.69%)
     
  • Silver

    24.88
    -0.37 (-1.45%)
     
  • EUR/USD

    1.1847
    -0.0020 (-0.1659%)
     
  • 10-Yr Bond

    0.8160
    -0.7970 (-100.00%)
     
  • Vix

    28.65
    -29.35 (-100.00%)
     
  • GBP/USD

    1.3130
    -0.0014 (-0.1037%)
     
  • USD/JPY

    104.6800
    +0.1200 (+0.1148%)
     
  • BTC-USD

    12,737.61
    +1,680.61 (+15.20%)
     
  • CMC Crypto 200

    255.42
    +10.53 (+4.30%)
     
  • FTSE 100

    5,776.50
    -112.72 (-1.91%)
     
  • Nikkei 225

    23,464.02
    -102.98 (-0.44%)
     

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Akcea Therapeutics, Inc. (Nasdaq -AKCA)

·2 mins read

BALA CYNWYD, PA / ACCESSWIRE / September 21, 2020 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Akcea Therapeutics, Inc. ("Akcea" or the "Company") (NASDAQ:AKCA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company's agreement with Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ("Ionis") for Ionis to acquire all of the outstanding shares of Akcea common stock that it does not already own for only $18.15 per share in cash.

The investigation concerns whether the Akcea Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Ionis is paying too little for the Company. For example, the deal consideration is well below the 52-week high of $22.79 for Akcea stock.

If you own shares of Akcea stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC, who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, visit http://www.brodskysmith.com/cases/akcea-therapeutics-inc-nasdaq-akca/, or call toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC



View source version on accesswire.com:
https://www.accesswire.com/607002/SHAREHOLDER-NOTICE-Brodsky-Smith-LLC-Announces-an-Investigation-of-Akcea-Therapeutics-Inc-Nasdaq-AKCA